Inhibition of P2X7 Purinergic Receptor Ameliorates Cardiac Fibrosis by Suppressing NLRP3IL-1β Pathway

Abstract EN

P2X7 purinergic receptor (P2X7R) has been implicated in several cardiovascular diseases.

However, whether it regulates cardiac fibrosis remains elusive.

Herein, its involvement in the development of cardiac fibrosis was examined using a transverse aortic constriction (TAC) mice model and cardiac fibroblasts (CFs) hyperstimulated by TGF-β1 for 48 hours.

Results showed that TAC and TGF-β1 treatment increased the expression of P2X7R.

Silencing of P2X7R expression with siP2X7R ameliorated TGF-β1 effects on fibroblasts activation.

Similarly, P2X7R inhibition by Brilliant Blue G (BBG) reduced mRNA and protein levels of profibrosis markers, while the P2X7R agonist BzATP accelerated the TGF-β1-induced CFs activation.

Moreover, it was found that TGF-β1-induced CFs activation was mediated by the NLRP3/IL-1β inflammasome pathway.

BBG or siP2X7R treatment suppressed NLRP3/IL-1β pathway signaling.

In vivo, BBG significantly alleviated TAC-induced cardiac fibrosis, cardiac dysfunction, and NLRP3/IL-1β activation.

Collectively, our findings imply that suppressing P2X7R may limit cardiac fibrosis and abnormal activation of CFs.